[Home ] [Archive]    
:: Main About journal Editorial Board Current Issue Archive Submit an article Site Map Contact ::
:: Volume 10, Issue 1 (3-2021) ::
Int J Med Invest 2021, 10(1): 111-119 Back to browse issues page
Impact of Cyclosporine A on white blood cell counts and some physiological parameters in renal transplanted patients: A case control study
Sarhang Hasan Azeez *
Biology Department, College of Education, Salahaddin University-Erbil, Kurdistan Region, Iraq
Abstract:   (642 Views)

Cyclosporine A (CyA) is a lipophilic cyclic undecapeptide originally derived from the filamentous fungus Tolypocladium inflatum. CyA has been used as a potent immunosuppressive agent for the treatment of autoimmune diseases and a number of organ transplantations, such as kidney, liver, heart, and bone marrow, resulting in a significant improvement in clinical outcome. This study involved 30 renal transplanted patients whom received Cyclosporine A as an immunosuppressant after transplantation in order to reduce the receiver’s immune response against the donor’s tissue or graft rejection. Demographic patterns and total white blood cells and other serum parameters were evaluated in order to determine the effect of CsA within specific therapeutic regimen. Total WBC was significantly reduced in patients, Urea and creatinine were increased remarkably. Serum GPT, K+ and Ca+ were also significantly changed. Results showed that CsA might has a potential impact on decreasing the WBC counts and increasing the triglyceride, cholesterol and blood glucose and alters the liver function. The side effects of the drug was considered as a risk for hyperlipidemia and alters the liver enzymes activity.

Keywords: Cyclosporine A, WBC, renal function, liver function, renal transplantation
Full-Text [PDF 175 kb]   (78 Downloads)    
Type of Study: Research | Subject: General
References
1. 1. Mukherjee, S., & Mukherjee, U. (2009). A comprehensive review of immunosuppression used for liver transplantation. Journal of transplantation, 2009, 701464. https://doi.org/ 10.1155/2009/701464 2. Kokuhu, T., Fukushima, K., Ushigome, H., Yoshimura, N., & Sugioka, N. (2013). Dose adjustment strategy of cyclosporine A in renal transplant patients: evaluation of anthropometric parameters for dose adjustment and C0 vs. C2 monitoring in Japan, 2001-2010. International journal of medical sciences, 10(12), 1665–1673. https://doi.org/10.7150/ijms.6727 3. Kang, J. S., & Lee, M. H. (2009). Overview of therapeutic drug monitoring. The Korean journal of internal medicine, 24(1), 1–10. https://doi.org/10.3904/kjim.2009.24.1.1 4. Ismael, I., Azeez, S. (2019). Immunosuppressive Drugs and KidneyPost-transplant Diabetes Mellitus. Hospital Practices and Research, 4(2), 50-56. doi: 10.15171/hpr.2019.09 5. Penfornis A, Kury-Paulin S. Immunosuppressive drug-induced diabetes. Diabetes Metab. 2006 Dec;32(5 Pt 2):539-46. doi: 10.1016/s1262-3636(06)72809-9. PMID: 17130815. 6. Bansal N. (2015). Prediabetes diagnosis and treatment: A review. World journal of diabetes, 6(2), 296–303. https://doi.org/10.4239/wjd.v6.i2.296 7. Mahmud, N., Klipa, D., & Ahsan, N. (2010). Antibody immunosuppressive therapy in solid-organ transplant: Part I. mAbs, 2(2), 148–156. https://doi.org/10.4161/mabs.2.2.11159 8. Kalluri, H. V., & Hardinger, K. L. (2012). Current state of renal transplant immunosuppression: Present and future. World journal of transplantation, 2(4), 51–68. https://doi.org/10.5500/wjt.v2.i4.51 9. Elsayed ASI, Bayomy MFF, Azab AE. Effect of acute and chronic treatment of Cyclosporine A on liver and kidney functions in rats. J Appl Pharm Sci. 2016;6(03):116–119. 10. Bardet V, Junior AP, Coste J, Lecoq-Lafon C, Chouzenoux S, Bernard D, Soubrane O, Lacombe C, Calmus Y, Conti F. Impaired erythropoietin production in liver transplant recipients: the role of calcineurin inhibitors. Liver Transpl. 2006 Nov;12(11):1649-54. doi: 10.1002/lt.20898. PMID: 17058250. 11. Pan, M. G., Xiong, Y., & Chen, F. (2013). NFAT gene family in inflammation and cancer. Current molecular medicine, 13(4), 543–554. https://doi.org/10.2174/1566524011313040007 12. Howell J, Sawhney R, Testro A, Skinner N, Gow P, Angus P, Ratnam D, Visvanathan K. Cyclosporine and tacrolimus have inhibitory effects on toll-like receptor signaling after liver transplantation. Liver Transpl. 2013 Oct;19(10):1099-107. doi: 10.1002/lt.23712. PMID: 23894100. 13. Russell RG, Graveley R, Coxon F, Skjodt H, Del Pozo E, Elford P, Mackenzie A. Cyclosporin A. Mode of action and effects on bone and joint tissues. Scand J Rheumatol Suppl. 1992;95:9-18. doi: 10.3109/03009749209101478. PMID: 1475634. 14. Elsayed ASI, Jbirea JM, Azab AE. Effect of acute and chronic cyclosporine a treatment on haematological data in male albino rats. J Appl Biotechnol Bioeng. 2018;5(6):350-357 DOI: 10.15406/jabb.2018.05.00164 15. Khalil, M., Khalil, M., Khan, T., & Tan, J. (2018). Drug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians. Journal of transplantation, 2018, 9429265. https://doi.org/10.1155/2018/9429265 16. Boes, K. M., & Durham, A. C. (2017). Bone Marrow, Blood Cells, and the Lymphoid/Lymphatic System. Pathologic Basis of Veterinary Disease, 724–804.e2. https://doi.org/10.1016/B978-0-323-35775-3.00013-8 17. Yoon, H. E., & Yang, C. W. (2009). Established and newly proposed mechanisms of chronic cyclosporine nephropathy. The Korean journal of internal medicine, 24(2), 81–92. https://doi.org/10.3904/kjim.2009.24.2.81 18. Pazhayattil, G. S., & Shirali, A. C. (2014). Drug-induced impairment of renal function. International journal of nephrology and renovascular disease, 7, 457–468. https://doi.org/10.2147/IJNRD.S39747 19. Kohan, D. E., Inscho, E. W., Wesson, D., & Pollock, D. M. (2011). Physiology of endothelin and the kidney. Comprehensive Physiology, 1(2), 883–919. https://doi.org/10.1002/cphy.c100039 20. Sereno, J., Rodrigues-Santos, P., Vala, H., Rocha-Pereira, P., Alves, R., Fernandes, J., Santos-Silva, A., Carvalho, E., Teixeira, F., & Reis, F. (2014). Transition from cyclosporine-induced renal dysfunction to nephrotoxicity in an in vivo rat model. International journal of molecular sciences, 15(5), 8979–8997. https://doi.org/10.3390/ijms15058979 21. Takeda A, Uchida K, Haba T, Tominaga Y, Katayama A, Yoshida A, Oikawa T, Morozumi K. Chronic cyclosporin nephropathy: long-term effects of cyclosporin on renal allografts. Clin Transplant. 2001;15 Suppl 5:22-9. doi: 10.1034/j.1399-0012.2001.0150s5022.x. PMID: 11791791. 22. Sandilands, E. A., Dhaun, N., Dear, J. W., & Webb, D. J. (2013). Measurement of renal function in patients with chronic kidney disease. British journal of clinical pharmacology, 76(4), 504–515. https://doi.org/10.1111/bcp.12198 23. Agnieszka Korolczuk, Kinga Caban, Magdalena Amarowicz, Grażyna Czechowska, Joanna Irla-Miduch, "Oxidative Stress and Liver Morphology in Experimental Cyclosporine A-Induced Hepatotoxicity", BioMed Research International, vol. 2016, Article ID 5823271, 9 pages, 2016. https://doi.org/10.1155/2016/5823271 24. David, S., & Hamilton, J. P. (2010). Drug-induced Liver Injury. US gastroenterology & hepatology review, 6, 73–80. 25. Russmann, S., Kullak-Ublick, G. A., & Grattagliano, I. (2009). Current concepts of mechanisms in drug-induced hepatotoxicity. Current medicinal chemistry, 16(23), 3041–3053. https://doi.org/10.2174/092986709788803097 26. Maaike Kockx and Leonard Kritharides (October 3rd 2012). Cyclosporin A-Induced Hyperlipidemia, Lipoproteins - Role in Health and Diseases, Sasa Frank and Gerhard Kostner, IntechOpen, DOI: 10.5772/47866. Available from: https://www.intechopen.com/books/lipoproteins-role-in-health-and-diseases/ cyclosporin-a-induced-hyperlipidemia 27. Srinivas, T. R., & Meier-Kriesche, H. U. (2008). Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result. Clinical journal of the American Society of Nephrology : CJASN, 3 Suppl 2(Suppl 2), S101–S116. https://doi.org/10.2215/CJN.03510807 28. Lee, J.M., Kronbichler, A., Shin, J.I. et al. Current understandings in treating children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 36, 747–761 (2021). https://doi.org/10.1007/s00467-020-04476-9.
Add your comments about this article
Your username or Email:

CAPTCHA


XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Azeez S H. Impact of Cyclosporine A on white blood cell counts and some physiological parameters in renal transplanted patients: A case control study. Int J Med Invest. 2021; 10 (1) :111-119
URL: http://intjmi.com/article-1-602-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 10, Issue 1 (3-2021) Back to browse issues page
International Journal of Medical Investigation
Persian site map - English site map - Created in 0.04 seconds with 29 queries by YEKTAWEB 4331